bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The company is headquartered in San Antonio, Texas and currently employs 57 full-time employees. The company went IPO on 2022-08-26. The company develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.
Follow-Up Questions
Who is the CEO of bioAffinity Technologies Inc?
Ms. Maria Zannes is the President of bioAffinity Technologies Inc, joining the firm since 2014.
What is the price performance of BIAF stock?
The current price of BIAF is $2.9, it has decreased 1.28% in the last trading day.
What are the primary business themes or industries for bioAffinity Technologies Inc?
bioAffinity Technologies Inc belongs to Biotechnology industry and the sector is Health Care
What is bioAffinity Technologies Inc market cap?
bioAffinity Technologies Inc's current market cap is $2.8M
Is bioAffinity Technologies Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for bioAffinity Technologies Inc, including 0 strong buy, 0 buy, 3 hold, 1 sell, and 0 strong sell
